SOURCE: Radient Pharmaceuticals Corporation
TUSTIN, CA–(Marketwire – October 28, 2010) – Radient Pharmaceuticals Corporation (RPC) (
Through this dynamic mode of communication everyone from existing and prospective shareholders, the broad investment community at large, healthcare professionals and their patients can learn about Radient Pharmaceuticals and its portfolio of in vitro diagnostic (IVD) cancer tests and products. In addition, financial Advisors have the ability to distribute RPC Investor Channel content to clients and securely track consumption when campaigning to clients about RPC, enhancing Radient’s ability to scale consideration into new investor communities.
The site also features videos communicating RPC’s business model, target markets and international distribution, sales and growth strategy; RPC as an investment opportunity; updates and progress on RPC’s portfolio of cancer diagnostic products, including its FDA-approved Onko-Sure® IVD cancer test kit; and educational information specifically targeted towards patients, physicians and the healthcare community in general.
According to Mr. Douglas Maclellan, Executive Chairman and CEO of RPC, “As a publicly-traded Company, superior investor communications is of utmost importance to our executive management team. With the launch of RPC’s new Investor Relations Video Channel, we are expanding our traditional lines of communication to now include a multi-media platform that offers added flexibility, reach and the ability to disseminate relevant Company information in a ‘high-touch’. We are very excited to offer this service to our valued stakeholders.”
Videos are accessible and viewable through personal computers and handsets with a 3G connection by visiting http://investorchannel.radient-pharma.com. For additional information on Radient Pharmaceuticals and its portfolio of IVD cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.Radient-Pharma.com.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel) 206.310.5323
Click here to see all recent news from this company